Guide RNAs preparation for in-vitro CRISPR-Cas9 complex delivery targeting genes that affect wound healing. by Khatiwada, Prashant
University of Arkansas, Fayetteville 
ScholarWorks@UARK 
Biomedical Engineering Undergraduate Honors 
Theses Biomedical Engineering 
5-2021 
Guide RNAs preparation for in-vitro CRISPR-Cas9 complex 
delivery targeting genes that affect wound healing. 
Prashant Khatiwada 
Follow this and additional works at: https://scholarworks.uark.edu/bmeguht 
 Part of the Molecular, Cellular, and Tissue Engineering Commons 
Citation 
Khatiwada, P. (2021). Guide RNAs preparation for in-vitro CRISPR-Cas9 complex delivery targeting genes 
that affect wound healing.. Biomedical Engineering Undergraduate Honors Theses Retrieved from 
https://scholarworks.uark.edu/bmeguht/98 
This Thesis is brought to you for free and open access by the Biomedical Engineering at ScholarWorks@UARK. It 
has been accepted for inclusion in Biomedical Engineering Undergraduate Honors Theses by an authorized 







Guide RNAs preparation for in-vitro CRISPR-Cas9 complex delivery targeting 








Honors Thesis by Prashant Khatiwada 
Department of Biomedical Engineering 
College of Engineering 
University of Arkansas 








Faculty Mentor: Dr. Christopher Nelson 
Honors Coordinator: Dr. Kyle Quinn 
2  
   Table of Contents 
1.    Abstract ................................................................................................................................... 3 
2.    Introduction ............................................................................................................................. 4 
2.1      CRISPR/Cas9 ...................................................................................................................... 4 
2.2      dCas9- KRAB ..................................................................................................................... 4 
2.3      Lipid Transfection ............................................................................................................... 5 
2.4      Guide RNA ......................................................................................................................... 5 
2.5      Nuclear Factor-Kappa Light Chain Gene Enhancer of Activated B cells ........................... 6 
2.6      NFKBIZ .............................................................................................................................. 8 
2.7      Caveolin-1 ........................................................................................................................... 9 
3.    Materials and Methods .......................................................................................................... 10 
3.1       Guide RNA design ............................................................................................................ 10 
3.2        Oligos/ gRNA Stock ......................................................................................................... 12 
3.3            Plasmid Digestion ............................................................................................................. 12 
3.4            Phosphorylation of Primers ............................................................................................... 12 
3.5       Ligation ............................................................................................................................. 13 
3.6       Transformation .................................................................................................................. 13 
3.7       Cell Culture ....................................................................................................................... 14 
3.8       Transfection ....................................................................................................................... 14 
4.    Results ................................................................................................................................... 17 
4.1       Sanger Sequencing Verification ........................................................................................ 18 
4.2       Cells Transfection .............................................................................................................. 22 
5.    Discussion ............................................................................................................................. 24 
6. Conclusion ............................................................................................................................ 26 
7. Future Directions .................................................................................................................. 26 
8.    Acknowledgement ................................................................................................................ 27 
References .................................................................................................................................... 28 
3  
     1. Abstract 
CRISPR-Cas9 technology has widely been used as a viable genome engineering 
platform to make site-specific insertion, deletion, and breaks. The nuclease dead version 
of Cas9 or dCas9 can be used for the activation and repression of target gene sites using 
specific activation or repression domains. In this study, CRISPR guide RNAs were 
designed for a CRISPR inhibition approach to repress the transcriptional activity of the 
target genes. An expression plasmid vector composed of a U6 promoter sequence, BbsI 
restriction sites, and a chimeric gRNA sequence was digested, and the phosphorylated 
forward and reverse gRNAs were ligated with the plasmid vector. The expression 
plasmids were transformed in E.coli cells and plated on Agar plates for selective 
extraction of the expression plasmids with the desired gRNA sequence from the bacterial 
cells. The presence of gRNAs was confirmed in the expression vectors through Sanger 
sequencing, and the cloned gRNAs in the expression vectors were transfected into 
HEK293 cells along with dCas9-KRAB through a lipid-mediated delivery method. The 
gRNAs were designed for NF-κB, NFKBIZ, and Caveolin-1 genes, among which the 
gRNAs for NF-κB were transfected to the HEK293 cells. The target genes were chosen 
because of their upregulated expression at impaired wound healing conditions. NF-κB is 
associated with several physiological pathways, gene expression, and protein functions 
involved in wound healing. The upregulation of NF-κB is associated with the negative 
proliferative phase, extended inflammatory response, and altered phagocytic functions of 
macrophages (Khanna et al., 2010). An increased expression of NFKBIZ is linked with 
the upregulation of IL-6 gene expression causing extended inflammation (Trinh et al., 
2008), (Johnson et al., 2020). Over expression of Cav1 is known to affect the movement 






Clustered Regularly Interspaced Palindromic Repeats or CRISPR technology has 
introduced a new chapter in the world of genome engineering through its use with 
respective CRISPR-associated protein (Cas) nucleases. Originating from the type II 
CRISPR-Cas systems, CRISPR with Cas9 endonuclease uses a ribonucleic acid duplex to 
make double-strand breaks at specific targets in the DNA (Doudna & Charpentier, 2014). 
CRISPR-Cas9 can be used with a specific DNA target with an engineered single-guide 
RNA (sgRNA) upstream of a protospacer adjacent motif (PAM) sequence to make 
site-specific DNA cleavages. The sgRNA incorporates CRISPR RNA (crRNA) and 
trans-activating RNA (tracrRNA) such that the 5’ end of the sequence uses nucleotide 
base pair binding with a specific DNA site and double-stranded RNA complex at the 3’ 
end binds with the Cas9 (Jinek et al., 2012). 
 
 
2.2 dCas9- KRAB 
 
The nuclease-dead version of the Cas9 can be used for genome regulation, where a 
mutant Cas9 changes the regulation of the transcription of the genes and does not 
contribute to gene editing. Also called CRISPR interference or CRISPRi, dCas9 can be 
used as a gene silencing method by blocking the transcription of the genes. Using domains 
such as Krüppel-associated box (KRAB) with dCas9 helps in the repression of 
transcription in mammalian cells including human cells (Gilbert et al., 2013). Similarly, 
gene expression can be activated using activator domains like VP64 with dCas9, which is 
also called CRISPR activation (CRISPRa). Unlike Cas9 that makes a double-stranded 
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break in the target sequence through RuvC and HNH nuclease domains, dCas9 consists of 
the deactivated nuclease domains caused by the introduced mutations of the two nuclease 
domains. The nuclease dead Cas9 functions as a protein that binds with DNA and is 
guided by an RNA sequence. Thus, effectors like VP64 and KRAB induce an artificial 
transcription factor when combined with sgRNA (La Russa & Qi, 2015). 
 
2.3 Lipid Transfection 
 
            Lipid transfection uses a lipid complex that resembles the cell membrane’s 
phospholipid bilayer to deliver nucleic acids through the cell membrane into the 
cytoplasm and ultimately to the nucleus. Because lipids are fat-soluble molecules, 
lipid-mediated transfection uses small lipid vesicles to travel through bi-layer cell 
membranes which are hydrophilic towards the cytoplasm and extracellular matrix, and 
hydrophobic in between (Carter & Shieh, 2015). Lipofectamine Reagent, also 
considered as the “gold standard” for the efficient transfection of nucleic acids, can 




2.4 Guide RNA 
 
To design guide RNA for genome engineering applications, there are certain 
design criteria to be considered. Depending on the type of Cas9 nucleases and CRISPR 
approaches, the target region may differ with respect to the PAM sequence. In 
Streptococcus pyogenes Cas9 (SpCas9), for a CRISPRa approach, an ideal gRNA is 
considered to have a ~100 nucleotides window upstream of the Transcription Start Site 
(TSS) of the gene whereas, for a CRISPRi approach, a region with a ~100 nucleotides 
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window downstream to the TSS is considered ideal (Mohr et al., 2016). Guide RNAs with 
mismatches away from the PAM are more favorable than the guides whose mismatches 
are closer to the PAM. (Addgene, n.d.). The favorable GC content on the gRNA sequence 
varies based on the applications in different cell lines. In mammalian cells, a GC 
percentage of 40% to 60 % is considered favorable. The guide sequence is generally 
17-20 nucleotides long and is complementary to the target DNA. The PAM sequence for 
SpCas9 is 3 nucleotides long- NGG, where “N” can be a variable nucleotide of the target 
DNA. If the gRNAs are inserted with the U6 Promoter, a “G” nucleotide is preferred at 
the beginning of each guide sequence for the initiation of transcription (Schindele et al., 
2020). 
Using a specific restriction endonuclease, specific cuts can be made at the target 
DNA sites on a plasmid vector for a “classic cloning” approach. Using overhangs that are 
complementary to both the gRNA and the plasmid vector, the blunt ends can be joined 
using a ligation reaction, where a T4 DNA Ligase catalyzes the joining process of the 
complementary regions. Similarly, there are a number of cloning methods such as the 
Gateway® Recombination Cloning, Gibson Assembly, Golden Gate, Molecular Cloning, 
etc. which can be used for the insertion of desired gRNA sequences into the plasmid 
DNAs. (Addgene, n.d.). 
 
 
2.5 Nuclear Factor-Kappa Light Chain Gene Enhancer of Activated B cells: 
 
Nuclear Factor-κB or NF-κB is a transcription factor that activates various genes 
that are associated with cytokines, molecules for leukocyte adhesion, chemokines, and the 
survival of cells. NF-κB has an essential role behind the vascular complications and 
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dysfunction in diabetes among which the upregulated expression of tumor necrosis 
 
factor-α (TNF-α), transforming growth factor-β (TGF-β), B-cell lymphoma 2 (BcL2), and 
other pro-apoptotic genes trigger vascular dysfunction. (Collins & Cybulsky, 2001). 
Likewise, with activated NF-κB, the receptor for advanced glycation end-products 
(RAGE) experiences an increased expression along with other proinflammatory cytokines 
which promote the signaling for cell damage (Tobon-Velasco et al., 2014). Advanced 
glycation end products (AGEs) that bind with RAGE, and reactive oxygen species (ROS) 
are induced by Hyperglycemia and increased pro-inflammatory response through NF-κB 
activation (LV et al., 2016). Overproduction of NF-κB also leads to angiogenesis along 
with cell damage as it affects the gene expression of endogenous protective factors, 
vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and 
endothelin-1 (ET-1) (Kitada et al., 2010). Since the cell signaling molecules for NF-κB 
are activated because of hyperglycemia, primarily through the AGE pathway, the altered 
gene expression as well as protein functions can lead to irregularities in inflammation, 
blood flow, leukocyte adhesion, membrane permeability, and apoptosis (Rask-Madsen & 
King, 2010). 
The upregulation of NF-κB is indicative of negative physiological effects, wound 
healing, and other cellular functions in hyperglycemic/ diabetic conditions. While several 
growth factors, pathways, and genes are activated along with NF-κB, the regulation of 
NF-κB is controlled by its inhibitors. NF-κB has an amino acid domain, also known as the 
Rel homology domain, which is associated with NF-κB inhibitors or IκBs. The inhibitors 
keep the NF-κB dimers from entering the nuclear region and the dimers remain in the 
cytoplasmic region. With the phosphorylation and activation of IKK kinase complex, 
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consisting of heterodimers such as IKK-α, IKK-β, and IKK-γ subunits, the NF-κB 
inhibitors or IκBs are phosphorylated as well. The inhibitors are then polyubiquitinated 
and eventually degraded which triggers the movement of NF-κB from the cytoplasm to the 
nucleus (Collins & Cybulsky, 2001). 
NF-κB is associated with wound healing physiological processes, especially in 
diabetic conditions, because of its relationship with other growth factors. For instance, the 
increased levels of TNF-α cytokines are found in the macrophages of diabetic mice 
wounds, which indicates an extended inflammatory response. The defective phagocytic 
functions of macrophages derived from altered VEGF in diabetic animal models 
negatively affect the extracellular matrix deposition, therefore affecting the proliferative 
phase of wound healing and tissue repair (Khanna et al., 2010).  
 
 
2.6 Nuclear Factor of Kappa Light Polypeptide Gene Enhancer in B-    
Cells Inhibitor Zeta 
NFKBIZ is a single copy gene and codes for the IκBζ protein. The IκBζ protein 
binds with NF-κB p50 homodimers unlike other IκB proteins, and increases the 
expression of the IL-6 gene (Trinh et al., 2008). The expression of IL-6 is found to be 
upregulated in diabetic wound sites, therefore, resulting in inflammation that lasts longer 
and delayed wound healing (Johnson et al., 2020). Additionally, patients with Type 2 




Caveolin-1 or Cav1 is found upregulated in the biopsies of non-healing diabetic 
foot ulcers whereas they are downregulated in the healing wounds. Cav1 is associated 
with membranous glucocorticoid receptors (mbGRs) as well as epidermal growth factor 
receptors (EGFR) to interfere with the migration of keratinocytes and epithelial cells for 
wound closure. The knockdown of Cav1 using CRISPR/Cas9 indicated a regulated wound 
healing and epithelialization by negatively affecting the complexes of Cav1-mbGR and 
Cav1-EGFR (Jozic et al., 2019). For diabetes-induced oxidative stress on in vivo wounds 
and in vitro dermal fibroblasts, an upregulated Cav1 expression isolated Mdm2 away from 
p53 which negatively affected the fibroblasts from type-2 diabetic patients. The 
down-regulated expression of Cav1 at specific targets enhanced tissue repair and indicated 
the crucial role of Cav1 in delayed wound healing in diabetes as well as high oxidative 
stress causing cellular senescence (Bitar et al., 2013). 
            Cav1 binds with a widely distributed glycoprotein CD26 and regulates T-cell 
proliferation. When interacting proteins Tollip and IRAK-1 dissociate from Cav1, it 
upregulates CD86 through the activation of NF-κB (Ohnuma et al., 2005). 
           NF-κB has associations with several genes, signaling pathways, growth 
factors, and proteins including NFKBIZ and Caveolin-1, which are involved in 
wound-healing processes. 
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3. Materials and Methods 
 
3.1 Guide RNA design 
 
      The guide RNAs for NF-kB were designed and selected using online platforms: 
CRISPR RGEN Tools (rgenome, n.d.), NCBI-BLAST (NCBI, n.d.), UCSC Genome 
Browser (UCSC, n.d.). The forward and reverse primers were designed to align with the 
following nucleotide sequence: 
 
5’- CACC NNNNNNNNNNNNNNNNNNNN 3’ 
 
 3’- NNNNNNNNNNNNNNNNNNNN CAAA- 5’ 
 
            Where, CACC and CAAA at the 5’ regions were the sticky regions for the 
complementary forward and reverse primers respectively, and the “N” represented the 
guide RNA sequence nucleotides. 
The gRNA sequences for NF-kB in spCas9 
 
NF-kB: Forward Oligo NF-kB: Reverse Oligo 
1. GGGGAAGCCCGCACTTCTAG 1. CTAGAAGTGCGGGCTTCCCC 
2. GGGGGAAGCCCGCACTTCTA 2. TAGAAGTGCGGGCTTCCCCC 
3. GTGGGGGAAGCCCGCACTTCT 3. AGAAGTGCGGGCTTCCCCCAC 
4. GCGAGAGAGCATACAGACAGA 4. TCTGTCTGTATGCTCTCTCGC 
5. GTATGCTCTCTCGACGTCAG 5. CTGACGTCGAGAGAGCATAC 
 
 
Table 1.: The forward gRNA oligos listed with their respective reverse gRNA 
oligos for NF-kB 
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The gRNA sequences for NFKIZ in spCas9 
 
NFKBIZ: Forward Oligo NFKBIZ: Reverse Oligo 
1. GGGACGGCGCGGGCCAGTAC 1. GTACTGGCCCGCGCCGTCCC 
2. GGCGCGCCCCGAGTACGCAG 2. CTGCGTACTCGGGGCGCGCC 
3. GCTGCGCGCGGCTGCCTCCC 3. GGGAGGCAGCCGCGCGCAGC 
 
 
Table 2: The forward gRNA oligos listed with their respective reverse gRNA 
oligos for NFKBIZ 
 
 
The gRNA sequences for Cav1 in spCas9 
 
Cav1: Forward Oligo Cav1: Reverse Oligo 
1. GGGAGCCGTAGCTGTCGGAG 1. CTCCGACAGCTACGGCTCCC 
2. GCTAACCGCTCCGACAGCTA 2. TAGCTGTCGGAGCGGTTAGC 
3. GTGAGAAGTCAGCCTGGCGG 3. CCGCCAGGCTGACTTCTCAC 
 
 
Table 3: The forward gRNA oligos listed with their respective reverse gRNA 
oligos for Cav1 
 
In this study, of the designed gRNAs for NF-κB, NFKBIZ, and Cav1, only the 
gRNAs for NF-κB were transfected in the cells for further analysis. 
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3.2 Oligos/ gRNA Stock 
 
Each tube containing either the forward or the reverse guide RNA sequence was 
 
re-suspended with an appropriate amount of nuclease-free water to get final concentrations 
of 100 µM. The re-suspended oligos were stored at -20°C. 
 
 
3.3 Plasmid Digestion 
 
For the digestion of plasmid DNA containing U6 promoter sequence, chimeric 
gRNA sequence, BBsI restriction sites, the restriction enzyme BbsI was used. 1.13 µL of 
plasmid DNA was mixed with 2 µL of the restriction enzyme along with 10 µL of 10X 
cut buffer and 86.87 µL of sterile molecular bio water to get a plasmid stock of 100 µL. 
The plasmid stock was incubated at 37 °C for an hour to get a digested plasmid stock. The 
plasmid was run in an agarose gel electrophoresis to confirm the digestion of plasmids. 
 
 
3.4 Phosphorylation of Primers 
 
For each guide RNA, 8.5 µL of the oligo stock containing the forward guide RNA 
sequence, and 8.5 µL of the oligo stock containing the reverse guide RNA sequence were 
mixed along with 2 µL of T4 DNA Ligase Buffer, 1µL of T4 Polynucleotide Kinase 
(PNK), and 0.5 µL of Adenosine Triphosphate (ATP) in PCR tube strips. In a PCR block, 
the tube strips were run at 37 °C for 60 minutes, 65 °C for 20 minutes, 95 °C for 2 
minutes, cooled to RT for 25 minutes and the temperature was dropped to 4°C before the 
guide RNAs were ligated with the plasmids. 
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3.5  Ligation 
 
            2 µL of digested plasmid was mixed with 1µL of phosphorylated oligos or insert 
along with 2 µL of T4 DNA Ligase Buffer, 1 µL of T4 Ligase and 14 µL of water. The 






STBL3 E. coli cells stored in -80oC were thawed in ice before mixing 50 µL of the 
 
E. coli cells with 2.5 µL of the ligated plasmid DNA. For transformation of the plasmids 
in the cells, they were incubated on ice for 30 minutes, heat-shocked for a minute at 42oC 
temperature, and placed on ice for 2 minutes. The plasmids-cells were mixed with 250 µL 
of Super Optimal Growth (SOC) media and incubated on a shaker at 37 o C temperature 
for 60 minutes. After incubation, they were plated on agar plates treated with Carbenicillin 
antibiotic and placed in an incubator overnight maintained at 37oC. 
Once the plates had visible colonies, a colony for each gRNA/ plasmid was 
collected and inoculated into 5 ml of LB Broth media and placed in a shaker at 37o C for 
16 hours. For selective transformation of the plasmids of interest, 5 µL of Carbenicillin 
was added for a 1:1000 antibiotic dilution. 
After 16 hours, the LB Broth with cells were centrifuged at 4000 rpm for 15 
minutes. The supernatant was discarded, and the pellet was used to extract the plasmid 
DNA using the QIAprep Spin Miniprep Kit (QIAGEN, n.d.). The extracted plasmids were 
sequenced through the Sanger sequencing services from Eurofins Genomics LLC. 
(Eurofins Genomics, n.d.). 
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3.7 Cell Culture 
 
Frozen HEK293 cells were thawed in a water bath at 37°C and mixed with 
DMEM medium containing 100 units/ml of penicillin G sodium, 100 µg/ml of 
streptomycin, 4 mM of L-glutamine, 10% of fetal bovine serum. The media with the cells 
was centrifuged for 10 minutes, the supernatant was discarded, and the pellet obtained 
was resuspended with DMEM medium. The cells were transferred to a tissue culture flask 
and incubated at 37°C. The cells were passaged when they reached 70-80% confluency. 
For passaging the cells, the medium was aspirated and washed with 10 ml PBS. 5 ml of 
Trypsin-EDTA was added to the flask, incubated for 5 minutes and the growth medium 
was added to inhibit the function of Trypsin. The cells were diluted with Trypan Blue 
solution and counted in a hemocytometer before seeding around 180,000 cells along with 






            To transfect the cells in a 12-well plate, two microcentrifuge tubes were prepared 
for each well. 500 ng of dCas9-KRAB plasmid and 500 ng of the primers with gRNA 
were diluted in Opti-MEM™ Medium, and P3000™ Reagent in the first microcentrifuge 
tube and Lipofectamine™ 3000 Reagent was diluted in Opti-MEM™Medium in the 
second microcentrifuge tube. The contents of the two microcentrifuges were mixed by 
transferring the contents of the first tube to the second tube in a 1:1 ratio. The final 
mixture in each tube was transferred to the respective wells containing the cells using a 
micropipette while also gently rocking the 12-well plate in the process. 
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Wells A1 and A2 were added with the mixture (1:1 ratio) of 500 ng GFP-plasmid 
diluted in Opti-MEM™ Medium, and Lipofectamine™ 3000 Reagent diluted in 
Opti-MEM™Medium (Thermofisher, n.d.). Wells A1 and A2 served as the positive 
controls and the well A4 contained only the cell culture media to serve as a negative 
control. Wells A1, A2 were transfected with plasmids with GFP. Well A3 was transfected 
with the gRNA (GTGGGGGAAGCCCGCACTTCT) and dCas9-KRAB, well A4 was not 
transfected and served as the negative control. Wells B1 and C1 were transfected with the 
gRNA (GGGAAGCCCGCACTTCTAG) along with dCas9-KRAB, wells B2 and C2 
were transfected with the gRNA (GGGGGAAGCCCGCACTTCTA) along with 
dCas9-KRAB, wells A3 and C3 were transfected with the gRNA 
(GTGGGGGAAGCCCGCACTTCT) along with dCas9-KRAB, and wells B4 and C4 
were transfected with the gRNA (GTATGCTCTCTCGACGTCAG) along with 
dCas9-KRAB in duplicates. After 24 and 48 hours of transfection, the cells in the wells of 
the 12-well plate were imaged using Nikon Eclipse Ts2 inverted microscope. The positive 
control cells transfected with GFP were imaged with an Epi-fluorescence imaging setting 
and the cells transfected with dCas9-KRAB and gRNAs were imaged with a Diascope 
imaging setting. For the verification of transcriptional repression by dCas9-KRAB 
proteins in the transfected cells, the RNA extracted from the transfected and cultured cells 
using RNeasy Mini Kit (QIAGEN, n.d.) would be quantified. 
The primers for qPCR were designed and analyzed using online platforms like 
NCBI Primer-Blast (NBBI, n.d.), Origene (Inc., O.G.T. (n.d.)) and UCSC Genome 
Browser (UCSC, n.d.). 
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The designed forward and reverse primers for qPCR: NF-kB 
 
NF-kB: Forward Primer NF-kB: Reverse Primer 
1. 1CTGCCAACAGATGGCCC 1. CACCATGTCCTTGGGTCCAG 
2. AAAAGAACCACCAGCTTCAGA 2. GCAGTGCCATCTGTGGTT 
3. GTATTTCAACCACAGATGGCAC 3. CGGAAACGAAATCCTCTCTGT 
 
 
Table 4: The forward qPCR primers listed with their respective reverse qPCR 
primers for NF-kB 
 
 
The designed forward and reverse primers for qPCR: NFKBIZ 
 
NFKBIZ: Forward Primer NFKBIZ: Reverse Primer 
1. CCGATTCGTTGTCTGATGGACC 1. GCACTGCTCTCCTGTTTGGGTT 
2. TCAGACGGCGAGTTCTTAGAG 2. GAGAGTTCAGCATCAGGCCA 
3. ATGCTGTCACGTACTTGGGTTA 3. ATCCACAGCTTGGCCAGAAG 
 
 
Table 5: The forward qPCR primers listed with their respective reverse qPCR 
primers for NFKBIZ 
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The designed forward and reverse primers for qPCR: Cav1 
 
Cav1: Forward Primer Cav1: Reverse Primer 
1. CCAAGGAGATCGACCTGGTCAA 1. GCCGTCAAAACTGTGTGTCCCT 
2. CTGGTCAACCGCGACCCTAA 2. CTGGCCTTCCAAATGCCGTC 
3. TCGGAGCGGTTAGTTCGATT 3. TAGACACGGCTGATGCACTG 
 
 
Table 6: The forward qPCR primers listed with their respective reverse qPCR 
primers for Cav1 
4. Results 
 
4.1 Plasmid Digestion Verification 
 




Figure 1: 1% TBE agarose gel showed the presence of single bands on wells 3 and 4, 
corresponding to ~3.0 kilobases indicating cleaved plasmids. 
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The appearance of a single band in each of the two wells corresponding to ~3.0 
kilobases indicates that the plasmid samples were cleaved by the restriction enzyme BbsI, 
therefore retaining the 3223 bp or ~3.2 kilobases of the plasmid. 
 
 
4.2 Sanger Sequencing Verification 
 
 



























Figures (2a-2e): Alignment of the expression plasmid backbone (Seq_2) with the 
respective experimental plasmids containing gRNAs for NF-κB ( Seq_1). The presence of 
the forward gRNA inserts (highlighted in Blue in Seq_1) in the experimental vectors 
between the U6 Promoter sequence (green colored nucleotides) and the tracrRNA 
sequence (blue colored nucleotides). 
 
 












confirms the successful insertion of gRNAs in the plasmid vector used. Based on the 
Sanger Sequencing results analyzed on “Serial Cloner 2.1”, the first gRNA sequence was 
present from 4102 to 4121 base pairs, the second gRNA sequence was present from 4092 
to 4111 base pairs, the third gRNA sequence was present from 5462 to 5482 base pairs, 
the fourth gRNA sequence was present from 3743 to 3763 base pairs and, and the fifth 
gRNA sequence was present from 4234 to 4253 base pairs in the experimental plasmid 
vectors cloned with gRNAS. In figures 2a-2e. “Seq_1” represented the sequence of the 
plasmid vector with gRNA, and “Seq_2” represented the sequence of the uncleaved 
plasmid vector. All five gRNA inserts were present in the BBsI sites between the U6 
promoter (represented by the green-colored nucleotide bases in Seq_2 of Figure 2a-2e) 
and the chimeric RNA sequence (represented by the blue colored nucleotide bases in 
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Seq_2 of Figures 2a-2e). Each gRNA insert corresponded to the BBsI site of the uncut 
plasmid (~907-924 nt). 






TATATATCTTGTGGAAAGGACGAAACAC, followed by the BBsI site with 18 bp 
from 907 to 924 nt with the sequence CGGGTCTTCGAGAAGACC. From 925 to 1007 






4.3 Cells Transfection 
 
The wells A1 and A2 of the 12-well plate, represented in Figure 3a, showed the 
presence of GFP through the emission of green color when a fluorescent microscope was 
used to visualize the HEK293 cells. The presence of GFP in the cells indicates that the 
plasmids (pGFP) containing GFP were transfected into the cells using the Lipofectamine 
delivery method. Likewise, Figure 3b showed the growing cells in wells A3 and B1 that 
were transfected with plasmids containing gRNA, and plasmids containing dCas9-KRAB. 
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The successful transfection of plasmids in the positive control wells represented in Figure 
3a indicates that the cultured cells had a viable transfection rate. 
Cells with GFP 
 
 
Figure 3a: Fluorescence Microscopy images of the HEK293 cells transfected 
with plasmids (pGFP) containing green fluorescent protein. 
 
Cells with dCas9-KRAB and expression plasmids 
 
 
Figure 3b: Microscopy images of the HEK293 cells transfected with dCas9-   




In Figure 1, the presence of single bands in wells 3 and 4 indicate that plasmid 
vectors indicate that one restriction enzyme was used to make a single cut in the plasmid 
vector. With a single cut made in the plasmid, the plasmid retained its original size (~3.2 
kb). Had there been more than one cut, two or more bands with the respective 
base-pairs would have appeared on the gel. The slow rate of migration shown by the bands 
in an electric field on gel electrophoresis indicates that the plasmid DNAs were not 
super-coiled because a super-coiled or an uncut plasmid DNA would have traveled down 
the gel towards the positive end at a higher rate. 
The data obtained in Figure 2(b) shows a missing nucleotide “T” in the U6 promoter 
sequence at 706th nucleotide in the plasmid backbone. However, the presence of the 
forward guide RNA insert in the BbsI restriction site indicates that the potential 
mismatch/noise was not significant in cloning the gRNA inserts into the expression 
plasmids. Similarly, the presence of all the forward gRNAs in their respective expression 
plasmids illustrated in Figures 2a-2e indicates the efficient digestion of plasmid, 
phosphorylation of oligos, and ligation of inserts into the expression vector. 
The presence of Green Fluorescence Protein in Figure 3(a) confirms a successful 
transfection of plasmids into the HEK293 cells. Since the GFP was transfected into the 
cells in the form of genes present in a plasmid vector, it indicates that the genes for GFP 
were able to code for the respective protein in the cells. This serves as a positive control 
for the other transfected cells present in the 12-well plate. Image 3(b) indicated that the 
cells were viably cultured and passaged, however the expression of the target genes in the 
cells through RNA extraction was not confirmed. 
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CRISPRi has many advantages when compared to the traditional methods of gene 
repression like RNAi, TALEN/ ZF, and miRNA sponges. One of the advantages of 
CRISPRi over the other most widely used RNAi approach is that there is a very minimal 
off-target effect with CRISPRi. CRISPRi complexes that are situated near the TSS work 
towards inhibiting transcription, and because of a narrow binding region CRISPRi 
complex around the TSS, the sequence space is shortened, where the bindings could 
increase off-target activity. Also, because CRISPRi is already very sensitive to the sgRNA 
and target DNA mismatches, the off-target effect is not significant enough to affect the 
transcription in the genes (Gilbert et al., 2013), (Kuscu et al., 2014), (Wu et al., 2014). 
CRISPRi can also be used to target the non-coding RNAs including miRNAs, lncRNAs, 
and the redundancy of miRNAs can be potentially targeted together. (Gilbert et al., 2013), 
(La Russa & Qi, 2015). 
The activation and regulation of NF-κB are associated with genes like CAV1 and 
NFKBIZ. The upregulated expression of NF-κB, CAV1, and NFKBIZ negatively affected 
wound healing. While it remains vague whether the upregulation of NF-κB directly 
up-regulates the expression of CAV1 and NFKBIZ, they all affect wound-healing and are 
interconnected through other protein attachments and pathways in the wound-healing 
physiological process. The upregulation of TNF-α, TGF-β, AGE, RAGE, ROS, and 
dysregulation in VEGF, PDGF, and ET-1, are linked with the over-expression of NF-κB. 
They affect inflammatory responses, ECM deposition, and other physiological processes 
that are crucial in wound healing. (Collins & Cybulsky, 2001), (Rask-Madsen & King, 




         The Sanger sequencing results indicate that the forward guide RNA sequences were 
successfully inserted in the plasmid backbone at the BbsI restriction sites after the plasmid 
vector was digested and confirmed through an agarose gel electrophoresis. Likewise, the 
presence of GFP protein in the positive control indicated that the plasmids with the GFP 
gene were transfected and transcribed into the cultured HEK293 cells. This indicates that 
the extracted RNA from the transfected cells could potentially have an expressed dCas9-
KRAB and gRNA complex for a repressed expression of target genes. 
 
 
7. Future Directions 
 
Using pre-designed forward and reverse primers for qPCR, the mRNA expression 
for NF-κB would be assessed through the RNA extracted from the transfected cells. The 
use of dCas9-KRAB indicates that a downregulated gene expression of NF-κB is to be 
expected. Downregulated RNA expression would indicate a successful CRISPRi approach 
using dcas9-KRAB. Since NF-κB is linked with many pathways and proteins that affect 
wound healing, successful in-vitro gene repression through dCas9-KRAB could be 
optimized and designed for potential in vivo studies. The plasmid vectors with the cloned 
gRNAs for NFKBIZ and Cav1 could be transfected with a similar approach as mentioned 
in this study. The relationship between NF-κB, NFKBIZ and Cav1 can be explored, and 
their collective roles in wound healing can be studied using a multiplexed genome 
engineering approach, by introducing a stabilizer tertiary RNA in the CRISPR/Cas 
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